ArticleFrontiers in oncology2025
Mitochondrial non-coding RNAs as novel biomarkers and therapeutic targets in lung cancer integration of traditional bioinformatics and machine learning approaches.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer diagnosis requires cost-effective biomarkers. Mitochondrial non-coding RNAs (mtRNAs) represent unexplored diagnostic targets. Methods: We analyzed TCGA-LUAD/LUSC miRNA-seq data to identify mtRNAs via mitochondrial genome alignment. Machine learning algorithms (SVM, Random Forest, Logistic Regression) classified samples using differentially expressed mtRNAs (P < 0.01, |log2FC| > 1). Top-ranked t00043332 was functionally validated in A549/PC9 cells. Results: Ten mtRNAs distinguished cancer from normal tissues. Random Forest and Logistic Regression achieved superior classification (AUC > 0.92) versus SVM. Nine mtRNAs were upregulated, one downregulated in cancer. No survival associations were observed. t00043332 overexpression promoted proliferation, migration, invasion, and apoptosis resistance. Conclusion: mtRNAs serve as effective lung cancer diagnostic biomarkers through integrated traditional and AI approaches. t00043332 functions as an oncogene, providing therapeutic targets and advancing biomarker discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.